These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21370407)

  • 21. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
    Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
    Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
    Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
    Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
    Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
    Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPM1D is a potential target for 17q gain in neuroblastoma.
    Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
    Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.
    Lastowska M; Van Roy N; Bown N; Speleman F; Roberts P; Lunec J; Strachan T; Pearson AD; Jackson MS
    Med Pediatr Oncol; 2001 Jan; 36(1):20-3. PubMed ID: 11464884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results.
    Combaret V; Iacono I; Bréjon S; Schleiermacher G; Pierron G; Couturier J; Bergeron C; Blay JY
    Cancer Genet; 2012 Dec; 205(12):657-64. PubMed ID: 23265803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12-21) in a patient with neuroblastoma].
    Laureys GG
    Verh K Acad Geneeskd Belg; 1995; 57(5):389-422. PubMed ID: 8571670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
    Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
    J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
    Plantaz D; Mohapatra G; Matthay KK; Pellarin M; Seeger RC; Feuerstein BG
    Am J Pathol; 1997 Jan; 150(1):81-9. PubMed ID: 9006325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of segmental alterations determines progression in neuroblastoma.
    Schleiermacher G; Janoueix-Lerosey I; Ribeiro A; Klijanienko J; Couturier J; Pierron G; Mosseri V; Valent A; Auger N; Plantaz D; Rubie H; Valteau-Couanet D; Bourdeaut F; Combaret V; Bergeron C; Michon J; Delattre O
    J Clin Oncol; 2010 Jul; 28(19):3122-30. PubMed ID: 20516441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variety and complexity of chromosome 17 translocations in neuroblastoma.
    Schleiermacher G; Raynal V; Janoueix-Lerosey I; Combaret V; Aurias A; Delattre O
    Genes Chromosomes Cancer; 2004 Feb; 39(2):143-50. PubMed ID: 14695994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma.
    Theobald M; Christiansen H; Schmidt A; Melekian B; Wolkewitz N; Christiansen NM; Brinkschmidt C; Berthold F; Lampert F
    Genes Chromosomes Cancer; 1999 Sep; 26(1):40-6. PubMed ID: 10441004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics.
    Vandesompele J; Michels E; De Preter K; Menten B; Schramm A; Eggert A; Ambros PF; Combaret V; Francotte N; Antonacci F; De Paepe A; Laureys G; Speleman F; Van Roy N
    Int J Cancer; 2008 Mar; 122(5):1177-82. PubMed ID: 17973261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays.
    Squire JA; Pei J; Marrano P; Beheshti B; Bayani J; Lim G; Moldovan L; Zielenska M
    Genes Chromosomes Cancer; 2003 Nov; 38(3):215-25. PubMed ID: 14506695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
    Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
    J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automatic detection and genetic profiling of disseminated neuroblastoma cells.
    Méhes G; Luegmayr A; Hattinger CM; Lörch T; Ambros IM; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):205-9. PubMed ID: 11464886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
    Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
    Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.